DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, is sharing the results of its studies on anxiety and depression at the American Psychological Association (“APA”) annual convention. The three-day convention begins today and runs through Aug. 6, 2022; it is being held virtually and in person in Minneapolis, Minnesota. According to the announcement, the new research underscores the value of Dario’s integrated behavioral health solution to help people connect to effective care that is works best for their needs. Dario’s studies evaluated the impact of a digital behavioral health solution for people living with clinically elevated levels of depression, with findings that indicate 72% of users experienced a reduction of symptoms during 12 weeks of participation. In addition, 44% of study participants reported clinically significant reductions in their levels of depression during the same timeframe. A second study noted that 68% of people living with severe or moderate anxiety improved their symptoms following 12 weeks of utilizing the platform, with 40% of participants with severe levels of anxiety seeing a clinically significant reduction during the evaluation period. “Depression, anxiety and chronic conditions have a complicated and bidirectional relationship, making it critical to ensure Dario members are receiving the care they need to help manage both,” said DarioHealth VP of clinical and scientific affairs and supervisor of the studies Yifat Hershcovitz, PhD, in the press release. “Our latest studies provide further evidence that our solutions provide members with the care they need to help improve their overall health with effective, convenient digital tools.”
To view the full press release, visit https://ibn.fm/TOTJm
About DarioHealth Corp.
DarioHealth Corp. is a leading digital therapeutics (“DTx”) company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition platform. The company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. DRIO’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.